ICIs, exemplified by antibodies targeting programmed cell death protein 1 (PD-1), programmed cell death ligand 1 (PD-L1), and cytotoxic T-cell-associated protein 4 (CTLA-4), have revolutionized the field of cancer treatment [119], [120]. This evidence concerns the gene PDCD1 and cancer.